文献速递免疫规划传染病防控与疫情报告

人乳头瘤病毒疫苗后未增加吉兰-巴雷综合征风险:英格兰自我对照病例系列研究

No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: A self-controlled case-series study in England.
PubMed 文献 · Vaccine · 2017-02-27

在英格兰12–18岁女孩中,利用医院 Episode Statistics 数据至2016年3月,采用自我对照病例系列法评估HPV疫苗接种后3、6、12个月内吉兰-巴雷综合征入院风险,未发现风险增加证据,并可排除约每百万剂1例的风险。

要点

  • HPV疫苗接种后3个月风险期相对发生率为1.04(95%CI 0.47–2.28),未见风险增加。
  • 6个月风险期相对发生率0.83(95%CI 0.41–1.69),12个月风险期1.10(95%CI 0.57–2.14)。
  • 基于相对发生率95%CI上限和英格兰HPV疫苗接种剂数,可排除约每百万剂1例的风险。

核心结论

  • 未发现英格兰HPV疫苗接种后吉兰-巴雷综合征风险增加的证据,并可排除约每百万剂1例的风险。

研究设计与样本

  • 自我对照病例系列研究,数据来自英格兰医院 Episode Statistics 至2016年3月,纳入11–20岁、有资格接种HPV疫苗的女性吉兰-巴雷综合征 Incident 病例。
  • 诊断由全科医生确认并提供HPV疫苗接种日期,分析纳入可联系到全科医生、至少接种一剂且吉兰-巴雷综合征确诊或可能病例的已接种女孩。
  • 评估任何剂量后3个月(主要风险窗口)、6个月和12个月内入院风险,对年龄、季节和时间段进行调整,并评估2012年从二价疫苗改为四价疫苗前后的风险。

主要发现

  • 初始识别244例,最终纳入100名女孩的101次发作。
  • 任何剂量后3、6、12个月内分别发生9、14、24次吉兰-巴雷综合征入院。
  • 3个月风险期相对发生率1.04(95%CI 0.47–2.28),6个月0.83(95%CI 0.41–1.69),12个月1.10(95%CI 0.57–2.14)。
  • 限制于79例确诊病例时,3个月风险期相对发生率1.26(95%CI 0.55–2.92);四价疫苗相对发生率1.61(95%CI 0.39–6.54),二价疫苗0.84(95%CI 0.30–2.34)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the risk of Guillain-Barré syndrome (GBS) after human papilloma virus (HPV) vaccine given to 12-18year old girls in England. METHODS: Hospital Episode Statistics (HES) were searched using data to March 2016 to identify incident cases of GBS in female patients aged from 11 to 20years eligible to have received the HPV vaccine since its introduction as a 3 dose schedule in September 2008. Diagnosis was confirmed by the case's general practitioner (GP) who also provided HPV vaccination dates. The risk of admission within 3months (primary risk window) 6 and 12months of any dose was assessed using the self-controlled case-series (SCCS) method in vaccinated girls with age, season and time-period adjustment. The risk before and after the change in 2012 from bivalent vaccine to quadrivalent vaccine was also assessed. RESULTS: A total 244 episodes were initially identified which reduced to 101 episodes in 100 girls when just including cases where the GP could be contacted, at least one vaccine dose was given, and GBS was confirmed or classed as probable. Nine, 14 and 24GBS admissions occurred within 3, 6, 12months of a dose respectively. The relative incidence (RI) for the 3month risk period was 1.04 (95% confidence interval 0.47-2.28), for the 6month period 0.83 (0.41-1.69) and for the 12month period 1.10 (0.57-2.14). When restricting to 79 confirmed cases the RI in the 3month risk period was 1.26 (0.55-2.92) and the RI 1.61 (0.39-6.54) for quadrivalent vaccine compared to 0.84 (0.30-2.34) for bivalent. CONCLUSION: We found no evidence of an increased risk of GBS following HPV vaccination in England and, based on the upper end of the 95% CI for the RI and the number of HPV vaccine doses given in England, can exclude a risk of about 1 per million doses.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Andrews N, Stowe J, Miller E, et al. No increased risk of Guillain-Barré syndrome after human papilloma virus vaccine: A self-controlled case-series study in England. Vaccine. 2017. PMID: 28245941. doi:10.1016/j.vaccine.2017.01.076

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。